Evaluation of in vitro Combined Antibacterial Activity of Some Commonly Used Antibiotics of Choice against Urinary Tract Infection Pathogens by Activity Index Profile.
Barre latérale de l'article
Contenu principal de l'article
Résumé
Evaluation of the in vitro combined antibacterial activity of antibiotics of choice: ciprofloxacin ((C), penicillin (P), trimethoprim-sulfamethoxazole (TMP-SMX), and cefixime (CX) against authochthonous and allochthonous urinary tract infection (UTI) pathogens: Escherichia coli (EC), Pseudomonas aeruginosa (PA), coagulase-negative Staphylococcus aureus (CONSA): Staphylococcus saprophyticus (SS) and Staphylococcus aureus (SA) was carried-out at 1xMIC, by the modified agar-well diffusion technique and the nature of the interactions assessed by activity-index profile (AIP). The preliminary antibacterial sensitivity assayed by agar-well diffusion technique showed excellent antibacterial activity of the agents against the tested UTI pathogens with inhibition zone diameters (IZD) within the range (20.0 – 50.0 mm), except cefixime, which was fairly active against EC and CONSA, with IZD of 12.0 mm; and inactive against PA and SA. The antibacterial activity of the agents was in the descending order: C > P > TMP – SMX > CX. The minimum inhibitory concentrations (MICs) of the active agents against the UTI pathogens determined by macrobroth-dilution technique were within the range: C (0.00781 – 0.0098 mg/ml), P(0.12 mg/ml); and TMP – SMX (4.80 – 0.60 mg/ml), with corresponding qualitative inhibitory potency, within the range (12.0 – 38.0 mm) for the UTI pathogens, except TMP-SMX which was inactive against SA. The interactions of the agents at 1xMIC against the UTI pathogens showed qualitative inhibitory activity within the range (9.0 – 25.0 mm), which were comparatively assessed by the AIP, indicating predominantly synergism and lessly indifferent for EC, CONSA and SA; and total antagonism for PA.
Téléchargements
Renseignements sur l'article
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
Références
Akunyili DN, Akinbue IP (1995). Handbook of Drug Interactions (Led). Kelu-printing and publishing company Enugu , Nigeria. pp 1 – 37.
Amdekar S, Singh V, Singh DD (2011). Probiotic therapy: immunomodulting approach towards urinary tract infection. Curr. Microbiol. Biol., 63(5): 484 – 490.
Andrew JM (2001). Determination of minimum inhibitory concentration. J. Antimicrob. Chemother. , 48 (Suppl. 1): 15 – 16.
Azzarone G, Liewehrs O’Connork (2007). Cystitis. Paediat. Rev., 28(12): 474 – 476.
Baron JE, Finegold SM (1990). Methods for testing antimicrobial effectiveness. In: C. V. Mosdy(ed). Bailey Scotts Diagnostic Microbiology (8ed). Missouri, USA.
Bhatt RG, Kary TA, Place FC (2011). Pediatric urinary tract infections. Med. Clin. North America, 29(3): 637 – 643.,
Chait BT, Williams K, Scmidt O (2007). Antibiotics interaction. J. Antimicrob. Chemother., 38 (Suppl. A): 12 – 15.
Colgan R, Williams M, Johnson JR (2011). Discuss an treatment of acute pyelinephritis in women. America Fam. Physician, 84(5): 519 – 526.
Collins CH, Lyne A (1979). Microbiological Methods (4ed) . Butterworth, London.
Conway PH, Cnaan A, Zaoutis T, Henry BV, Grundmeiur RW, Keren R (2007). Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. J. Antimicrob. Chemother. 298(2): 179 – 186.
Davies J (1979).General mechanism of antimicrobial resistance. Rev. Infect. Dis., 1:23 – 28.
Davies J (1984). Microbial resistance to antimicrobial agents. In: Rsituccia, A. M. and B. A. Cunda (ed). Antimicrobial Therapy. Raven Press-New York.
Dielubanza EJ, Schaeffer AJ (2011). Urinary tract infections in women. Med. Clin. North America.,95 (1): 27 – 11.
Ekong US, Mgbor NM, Moneke AN, Obi SKC (2004). Evaluation of the antimicrobial and some pharmacokinetic properties of an antibiotic –substance produced by an environmental Aspergillus species SK2, isolated from Nigerian soil. Nig. J. Microbiol., 18 (1-2), 199 – 206.
Ekong US, Mgbii AI, Adikwu MU (2008). Evaluation of the in vitro combination effect of colloidal silver concentrate on the antifungal activity of ethanolic extract of the lichen USnea subfloridans. Nig. Ann. Nat. Sci., 8(1): 1 – 5.
Ekong US, Odenigbo NS, Adikwu MU (2010). Effect of colloidal silver concentrate on the antibacterial activity of ethanolic extract of lichen: Parmelia perlata. J. Pharm. Allied Sci., 7(3): 227 – 331.
Ekong US (2013). Production, characterization and antimicrobial spectra of antibiotic substances from Streptomyces species isolated from different soil samples in Uyo, Nigeria. Ph.D dissertation, University of Nigeria, Nsukka, Nigeria.
Finch RG (2011). Antimicrobial therapy: principles of use of antibiotics combinations: quinolones and ?-lactams. Medicine, 39: 35 – 40.
Fleming A (1980). Classes in Infectious Diseases: On the antibacterial action of cultures of Penicillin, with special reference to their use in the isolation of B. influence Brit. J. Exptal. Pathol., 10:226 – 236.
Foster RT (2008). Uncomplicated tract infections in women. Obstet. Gynecol. North America, 35(2): 235 – 248.
Gopal RG, Patel M (2009). Urinary tract infection in hospitalized elderly patients in the united Kingdom,: the importance of making accurate diagnosis in the post broad-spectrum antibiotics era. J. Antimicrob. Chemother., 63:5 – 6.
Gould CU, Umscheid CA, Agarwal RK, Kuntzapergues DA (2010). Guidelines for prevention of catheter-asociated urinary tract infections. Infect. Control Hosp. Epidemiol., 31(4): 319 – 326.
Gruenberg RN (1994). Changes in urinary tract pathogens and their antibiotic sensitivity 1971 – 1972. J. Antimicrob. Chemoth., 33: (Suppl. A)1.
Harter DP (1995). Important Drug Interactions: In: G.B katzung (ed). Basic And Clinical Pharmacology (6ed). Appleton-Lange, Connecticutt, USA. P. 986 – 994.
Katherine MK, Susan E (2007). Routes of transmission of infectious diseases agents from modes of introduction of exotic animal disease agents. J. Vet. Med. 54: 221 – 235.
Kuroda M, Yamashita A, Hirakawa H (2003). Whole genome sequence of Staphylococcus saprophyticus reveals the pathogenesis of uncomplicated urinary tract infection. Proc. Natl. Acad. Sci, USA. 102 (37): 113272 – 113277.
Lane DR, Takhar SS (2011). Diagnosis and Management of urinary tract infection and pyelonephritis Emergency Med. Clinic North-America, 29(3): 539 – 552.
LichtenBerger P, Hooton TM (2008). Complicated urinary tract infections. Curr. Infections Urol. Clin. North America, 35:13 – 22
Lorian V (1991). Antibiotics in Laboratory Medicine: Methods Used to Assess the Activity of Antimicrobial Combinations (3ed). Williams and Wilkins, Baltimore, Maryland, USA. P. 434 – 444.
Mandell GL, Douglass RG, Bernett JE (2000). Principles and Practices of Infectious Diseases. Churchill, Livingstone, Phladelphia, USA. Pp 222 – 225.
Neal DE Jr (2008). Complicated urinary tract infections. Urol. Clin. North America, 35: 13 – 22.
Neu AC (1983). The emergence of bacterial resistance and its empirical therapy. Rev. Infect. Dis., 5: 59 – 63.
Neu HC (1984). Changing mechanisms of bacterial resistance Amer. J. Med., 776: 11 – 13.
Nicolle LE (2005). Complicated urinary tract infection in adults. Can J. Infect. Dis. Med. Microbiol., 16: 349 – 360.
Nicolle LE (2008). Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. Urolog. Clin. North American, 35(1): 1 – 2.
Nicolle LE, Bradley S, Colgan R (2006). Infectious diseases society of America: Guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin. Infect. Dis., 40:634 – 654.
Nikaido A (1989). Outer-membrane barrier as a mechanism of antimicrobial resistance. Antimicrob. Agents Chemother., 33: 1831 – 1836.
Nikaido H, Normark S (1987). Sensitivity of Escherichia coli to various ?- lactams is determined by the interplay of outer-membrane permeability and ?- lactamases: a qualitative predictive treatment. J. Mol. Biol., 1: 29 – 36.
Nikaido H, Rosenberg EX, Foulds J (1983). Porin channels in Escherichia coil.: studies with ?-lactamase in intact cells. J. Bacteriol, 153: 232 – 240.
Okore VC (2009). Principles of Pharmaceutical Microbiology (2ed). Ephrata Publishers, Nsukka, Nigeria. P. 196 – 260.
Phillipion A, Lehra R, Jacoby G. (1989). Extended spectrum of ?- lactamses. Antimicrob. Agents Chemother., 3:131 – 1136.
Rahal JJr. (1978). Antibiotics combinations: the clinical relevance of synergy and antagonism. Medicine, 57: 179 – 195.
Rossi R, Porta S, Canovi B (2010). Overview on cranberry and urinary tract infections in females. J. Clin. Gastrointerol. (44Suppl. 1). 86 – 92.
Roy CC, Segura C, Tirado M, Reig R, Hermida M, Teruses D, Fo A (1985). Frequency of plasmid determined ? –lactmases in 680 consecutively isolated strains of enterobacteriaceae. Euro. J. Clin. Microbiol., 4: 146 – 147.
Rupp ME, Soper DE, Archer GL (1992). Colonization of female genital tract with Staphylococcus saprophyticus. J. Clin. Microbiol., 30 (11): 2975 – 2979.
Rybak JM, McGrath JB (1996). Combined antimicrobial therapy for bacterial infections: guidelines for clinicians. Drugs, 52(3):309 – 402.
Sabbath D, Lorian V (1997). In vitro tests for antibacterial activity of antibiotics in combinations. In: A Bodi, J. T. Bartola, and J. E. Prier (eds).The Clinical laboratory As An Aid in Chemotherapy of Infectious Diseases. University Park press, Baltimore, Maryland, USA. P 196 – 227.
Salvatore S, Cattori E, Eiesto G, Serati M, Soruce P, Tonella M (2011). Urinary tract infections in women. Euro J. Obste. Gynecol. Repro. Biol., 156 (3): 131 – 136.
Schaeffer AJ (2002). Infections of the urinary tract. In Walsh, P. C., Refik, A B., Vangham, E. O., and Weri, A. J. (eds). Campbell’s Theology (ed). Saunders, Philadelphia, USA. P 515 – 602.
Schleifer KH, Kloos WE (1978). Isolation and characterization of Staphylococcus saprophyticus and description of three new species. Int’l J. Syst. Bacteriol., 25(1): 50 – 61.
Scottish MU (2010). Intercollegiate guidelines network: Management of suspected bacterial urinary tract infection in adults. NHS Qual. Improv. Scotland. 27:145 – 175.
Tatro DS (1992). Drug Interactions. In: E. T. Herfindal, D. R. Gourley and L. L. Hert. Clinical Pharmacy and Therapeutics (5ed). Williams and Wilikings , Baltimore, Maryland, USA. P. 37 – 44.
Tilton RC, Howard BJ (1987). Antimicrobial susceptibility testing. In: B. J. Howard (ed). Clinical and Pathogenic Microbiology. C. V. Mosby, Missouri, USA.
Vaara M, Barra T (1983). Polycations sensitized enteric bacteria to antibiotics. Antimicrobs. Agent Chemother., 24: 107 – 113.
Widerstorm M, Wistrom J, Sjostedt A, Monsen T (2012). Coafulase – negative staphylococcus; update on molecular epidemidogy and clinical presentation, with focus on Staphylococcus saprophyticus. Euro. J. Clin. Microbiol. Infect. Dis., 31 (7): 7 – 20.
Williams R (2000). Antimicrobial resistance: The facts. Essential Drug Monitor, 28/29:7 – 8.
Woodford HJ, George J (2011). Diagnosis and management of urinary tract infections in older people. Clin. Med., 11 (7): 80 – 83.
Zinner SN, Lasterky J, Grays H, Bernard C, Ryff IC (1981). In vitro and in vivo studies of three antibiotic combinations against Gram-negative bacteria and Staphylococcus aureus. Antimicrob. Agents Chemother., 20: 463 – 469.